| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Date of Report (date of earliest event reported): November 16, 2026 |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapy |
| 19 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
1.He is the Chief Executive Officer and Chief Scientific Officer of iBio, Inc. (the “Corporation”), a Delaware corporation, and is duly authorized by the Board of Directors of the Corporation to execute this instrument. |
| 15 Oct 2026 |
Form 4: Stoner Elizabeth, Director
Granted 38,000 Stock Option (right to buy) |
| 15 Oct 2026 |
Form 4: Kropotova Alexandra, Director
Granted 38,000 Stock Option (right to buy) |
| 15 Oct 2026 |
Form 4: Arkowitz David, Director
Granted 38,000 Stock Option (right to buy) |
| 15 Oct 2026 |
Form 4: Clark William D, Director
Granted 38,000 Stock Option (right to buy) |
| 15 Oct 2026 |
Form 4: Parada Antonio Bernardino Guimaraes, Director
Granted 38,000 Stock Option (right to buy) |
| 15 Oct 2026 |
Form 4: Sender Gary, Director
Granted 38,000 Stock Option (right to buy) |
| 14 Oct 2026 | SCHEDULE 13G |
| 13 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
BREAKTHROUGH ANTIBODIES FOR OBESITY AND CARDIOMETABOLIC DISEASES CORPORATE PRESENTATION • September 2026 |
| 04 Sep 2026 | ARS |
| 04 Sep 2026 |
Proxy statement: annual meeting on October 14, 2026
CEO pay $2.1M, up 42% · say-on-pay vote |
| 28 Aug 2026 | 10-K |
| 28 Aug 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, August 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its ... |
| 20 Aug 2026 | PRE 14A |
| 14 Aug 2026 | SCHEDULE 13G |
Loading...